THE INVENTION.

MIT Professors Klavs Jensen and Robert Langer and their graduate student Armon Sharei were focused on developing a more effective system for delivering materials directly into the cell cytosol – a significant challenge in many research and therapeutic applications.

Their team’s work, supported by the NIH and Koch Institute for Integrative Cancer Research, led to the development of the CellSqueeze platform.

STARTING A COMPANY.

Having received significant interest from the broader academic community, the inventors decided to start a company, SQZ Biotech, to explore and develop the potential of this promising technology.

With support from our angel investors, venture backers, and government funding sources, we have continued to develop the technology’s potential across a variety of applications with particular focus on the cell therapy space.

MAKING AN IMPACT.

Cell therapies have great potential to address our most challenging diseases. However, the difficulty of engineering patient cells in an effective, scalable manner has limited their impact. Our technology has overcome longstanding barriers in the field by facilitating more effective access to the intracellular space.

Through internal research programs and external partnerships, SQZ Biotech is leading a revolution in scientists’ approach to disease research and clinical therapies, developing novel methods to engineer cell function and harnessing the power of a patient’s own cells to combat disease more effectively across a broad range of indications.

Our Board of Directors

Amy Schulman

Amy Schulman

SQZ Executive Chair and Partner at Polaris Partners. Former Pfizer executive named one of Fortune’s 50 most powerful women in business in 2013.

Armon Sharei

Armon Sharei

SQZ Founder & CEO. Lead inventor of the CellSqueeze technology. Selected as one of the 30 Under 30 in Healthcare by Forbes in 2015.

Robert Langer

Robert Langer

SQZ Founder. MIT Institute Professor. Most cited engineer in history renowned for his contributions to the fields of drug delivery and tissue engineering.

Klavs Jensen

Klavs Jensen

SQZ Founder. Established leader in fabrication, testing, and integration of microsystems. MIT Chemical Engineering Department Chair.

Jonathan Fleming

Jonathan Fleming

Investment manager for over twenty seven years. Started and financed the growth of multiple companies. MIT Sloan lecturer.

Mark Murcko

Mark Murcko

Former CTO and SAB Chair of Vertex. Over 25 years of leadership experience in the biomedical field. Key contributor to seven marketed drugs.

Garry Nicholson

Garry Nicholson

President and Chief Executive Officer of XTuit Pharmaceuticals. Former head of global oncology at Pfizer.

Our Leadership Team

Amy Schulman

Amy Schulman

SQZ Executive Chair and Partner at Polaris Partners. Former Pfizer executive named one of Fortune’s 50 most powerful women in business in 2013.

Armon Sharei

Armon Sharei

SQZ Founder & CEO. Lead inventor of the CellSqueeze technology. Selected as one of the 30 Under 30 in Healthcare by Forbes in 2015.

Howard Bernstein

Howard Bernstein

SQZ Chief Scientific Officer. Over 25 years of experience in technology and drug development. Involved in the development of nine products, and holds 250 patents and patent applications.

Bruce Beutel

Bruce Beutel

SQZ Chief Business Officer. Over 25 years in pharmaceutical R&D management and Business Development with broad range of experience across disease areas, technologies, and deal structures.

SCIENTIFIC ADVISORS

Chris Love, PhD
Associate Professor of Chemical Engineering, Graduate Admissions Officer at MIT.

Ulrich von Andrian, MD, PhD
Immunologist & Professor of Microbiology and Immunobiology at Harvard University.

Tyler Jacks, PhD
Director of The Koch Institute and Professor of Biology, MIT.

Darrell Irvine, PhD
Professor of Materials Science & Engineering and Biological Engineering at MIT.

Arlene Sharpe, MD, PhD
Leader of the Dana-Farber Cancer Immunology Program.

MAJOR GRANT FUNDING SOURCES